During the last years, CDK4/6 inhibitors have changed the treatment landscape of hormone receptor‐positive and HER‐2‐negative breast tumors offering large progression‐free intervals to many patients with invasive breast cancer. This evidence concerns the gene NR4A1 and breast neoplasm.